Abstract
The kidney plays an important role in the regulation of plasma glucose. It is estimated that greater than 99% of the renal glucose filtered by kidney glomerulus is resorbed by sodium-dependent glucose co-transporters (SGLTs), and that SGLT2 located in the proximal renal tubule achieves the most of this assignment. Studies of SGLT2 inhibitors indicate that raising renal glucose excretion by inhibiting SGLT2 helps effectively normalize the plasma glucose levels in individuals with type 2 diabetes mellitus (T2DM). This review discusses the discovery of SGLT2 inhibitors and the related structure-activity relationship (SAR) studies. The clinical trial data of dapagliflozin is also involved.
Keywords: Dapagliflozin, phlorizin, sodium-dependent glucose co-transporter, structure-activity relationships, type 2 diabetes mellitus, regulation of plasma glucose, SGLT2 inhibitors, relatedstructure-activity relationship, insulin deficiency
Current Topics in Medicinal Chemistry
Title: Development of Sodium-Dependent Glucose Co-Transporter 2 Inhibitors as Potential Anti-Diabetic Therapeutics
Volume: 11 Issue: 12
Author(s): Low-Tone Ho, Suvarn S. Kulkarni and Jinq-Chyi Lee
Affiliation:
Keywords: Dapagliflozin, phlorizin, sodium-dependent glucose co-transporter, structure-activity relationships, type 2 diabetes mellitus, regulation of plasma glucose, SGLT2 inhibitors, relatedstructure-activity relationship, insulin deficiency
Abstract: The kidney plays an important role in the regulation of plasma glucose. It is estimated that greater than 99% of the renal glucose filtered by kidney glomerulus is resorbed by sodium-dependent glucose co-transporters (SGLTs), and that SGLT2 located in the proximal renal tubule achieves the most of this assignment. Studies of SGLT2 inhibitors indicate that raising renal glucose excretion by inhibiting SGLT2 helps effectively normalize the plasma glucose levels in individuals with type 2 diabetes mellitus (T2DM). This review discusses the discovery of SGLT2 inhibitors and the related structure-activity relationship (SAR) studies. The clinical trial data of dapagliflozin is also involved.
Export Options
About this article
Cite this article as:
Ho Low-Tone, S. Kulkarni Suvarn and Lee Jinq-Chyi, Development of Sodium-Dependent Glucose Co-Transporter 2 Inhibitors as Potential Anti-Diabetic Therapeutics, Current Topics in Medicinal Chemistry 2011; 11 (12) . https://dx.doi.org/10.2174/156802611795860915
DOI https://dx.doi.org/10.2174/156802611795860915 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Blood-Brain Barrier Interface in Diabetes Mellitus: Dysfunctions, Mechanisms and Approaches to Treatment
Current Pharmaceutical Design Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases
Current Drug Targets 11 Years of Cyanopyrrolidines as DPP-IV Inhibitors
Current Topics in Medicinal Chemistry Introduction: P2 Receptors
Current Topics in Medicinal Chemistry The Role of Orexin System in Antipsychotics Induced Weight Gain
Current Psychiatry Reviews Antipsychotics in the Treatment of Impulsivity in Personality Disorders and Impulse Control Disorders
Current Psychopharmacology Hyperglycemia Induced Changes in Liver: In vivo and In vitro Studies
Current Diabetes Reviews Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Interactions of Biologically Active Factors and Vascular Mediators During Hypertension in Pregnancy
Current Hypertension Reviews The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions
Current Medicinal Chemistry Prevention of Cardiovascular Diseases with Anti-Inflammatory and Anti- Oxidant Nutraceuticals and Herbal Products: An Overview of Pre-Clinical and Clinical Studies
Recent Patents on Inflammation & Allergy Drug Discovery The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design Metabolic Control Analysis and its Applications
Current Bioinformatics Metabolic Syndrome and Diabetic Atherothrombosis: Implications in Vascular Complications
Current Molecular Medicine Postmenopausal Hormone Therapy
Current Women`s Health Reviews Safety Aspects of Statins: Which Factors Create the Adverse Effects of Statins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) MicroRNAs: Biomarkers for Cardiovascular Disease in Patients with Diabetes Mellitus
Current Topics in Medicinal Chemistry Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region
Mini-Reviews in Organic Chemistry Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs